Questions and recommendations from the prior version of these guidelines without change Target population Adult patients (age ≥ 18 years) who have suspected low-grade diffuse glioma. Question What are the optimal neuropathological techniques to diagnose low-grade diffuse glioma in the adult? Recommendation Level I Histopathological analysis of a representative surgical sample of the lesion should be used to provide the diagnosis of low-grade diffuse glioma. Level III Both frozen section and cytopathologic/smear evaluation should be used to aid the intra-operative assessment of low-grade diffuse glioma diagnosis. A resection specimen is preferred over a biopsy specimen, to minimize the potential for sampling error issues. Target population Patients with histologically-proven WHO grade II diffuse glioma. Question In adult patients (age ≥ 18 years) with histologically-proven WHO grade II diffuse glioma, is testing for IDH1 mutation (R132H and/or others) warranted? If so, is there a preferred method? Recommendation Level II IDH gene mutation assessment, via IDH1 R132H antibody and/or IDH1/2 mutation hotspot sequencing, is highly-specific for low-grade diffuse glioma, and is recommended as an additional test for classification and prognosis. Target population Patients with histologically-proven WHO grade II diffuse glioma. Question In adult patients (age ≥ 18 years) with histologically-proven WHO grade II diffuse glioma, is testing for 1p/19q loss warranted? If so, is there a preferred method? Recommendation Level III 1p/19q loss-of-heterozygosity testing, by FISH, array-CGH or PCR, is recommended as an additional test in oligodendroglial cases for prognosis and potential treatment planning. Target population Patients with histologically proven WHO grade II diffuse glioma. Question In adult patients (age > 18 years) with histologically-proven WHO grade II diffuse glioma, is methyl-guanine methyl-transferase (MGMT) promoter methylation testing warranted? If so, is there a preferred method? Recommendation There is insufficient evidence to recommend MGMT promoter methylation testing as a routine for low-grade diffuse gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess the value of this and related markers for this target population. Target population Patients with histologically-proven WHO grade II diffuse glioma. Question In adult patients (age ≥ 18 years) with histologically proven WHO grade II diffuse glioma, is Ki-67/MIB1 immunohistochemistry warranted? If so, is there a preferred method to quantitate results? Recommendation Level III Ki67/MIB1 immunohistochemistry is recommended as an option for prognostic assessment. New recommendation Target population Adult patients (age ≥ 18 years) who have suspected WHO grade II diffuse glioma. Question Is testing for ATRX mutations helpful for predicting survival and making treatment recommendations? Recommendation There is insufficient evidence to recommend ATRX mutation testing as a means of predicting survival or making treatment recommendations. Target population Adult patients (age ≥ 18 years) who have suspected WHO grade II diffuse glioma. Question Does the addition of intraoperative optical histologic methods provide accuracy beyond the use of conventional histologic methods in diagnosis and management? Recommendation There is insufficient evidence at this time to suggest that intraoperative optical histologic methods offer increased diagnostic accuracy when compared to conventional techniques.

Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update

期刊论文
发表日期：

2025年1月2日

查看全文

Nataniel Mandelberg,
Tiffany R. Hodges,
Tony J. C. Wang,
Tresa McGranahan,
Jeffrey J. Olson,
Daniel A. Orringer

摘要

Questions and recommendations from the prior version of these guidelines without change Target population

Adult patients (age ≥ 18 years) who have suspected low-grade diffuse glioma.

Question

What are the optimal neuropathological techniques to diagnose low-grade diffuse glioma in the adult?

Recommendation

Level I Histopathological analysis of a representative surgical sample of the lesion should be used to provide the diagnosis of low-grade diffuse glioma.

Level III Both frozen section and cytopathologic/smear evaluation should be used to aid the intra-operative assessment of low-grade diffuse glioma diagnosis. A resection specimen is preferred over a biopsy specimen, to minimize the potential for sampling error issues.

Target population

Patients with histologically-proven WHO grade II diffuse glioma.

Question

In adult patients (age ≥ 18 years) with histologically-proven WHO grade II diffuse glioma, is testing for IDH1 mutation (R132H and/or others) warranted? If so, is there a preferred method?

Recommendation

Level II IDH gene mutation assessment, via IDH1 R132H antibody and/or IDH1/2 mutation hotspot sequencing, is highly-specific for low-grade diffuse glioma, and is recommended as an additional test for classification and prognosis.

Target population

Patients with histologically-proven WHO grade II diffuse glioma.

Question

In adult patients (age ≥ 18 years) with histologically-proven WHO grade II diffuse glioma, is testing for 1p/19q loss warranted? If so, is there a preferred method?

Recommendation

Level III 1p/19q loss-of-heterozygosity testing, by FISH, array-CGH or PCR, is recommended as an additional test in oligodendroglial cases for prognosis and potential treatment planning.

Target population

Patients with histologically proven WHO grade II diffuse glioma.

Question

In adult patients (age > 18 years) with histologically-proven WHO grade II diffuse glioma, is methyl-guanine methyl-transferase (MGMT) promoter methylation testing warranted? If so, is there a preferred method?

Recommendation

There is insufficient evidence to recommend MGMT promoter methylation testing as a routine for low-grade diffuse gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess the value of this and related markers for this target population.

Target population

Patients with histologically-proven WHO grade II diffuse glioma.

Question

In adult patients (age ≥ 18 years) with histologically proven WHO grade II diffuse glioma, is Ki-67/MIB1 immunohistochemistry warranted? If so, is there a preferred method to quantitate results?

Recommendation

Level III Ki67/MIB1 immunohistochemistry is recommended as an option for prognostic assessment.

New recommendation Target population

Adult patients (age ≥ 18 years) who have suspected WHO grade II diffuse glioma.

Question

Is testing for ATRX mutations helpful for predicting survival and making treatment recommendations?

Recommendation

There is insufficient evidence to recommend ATRX mutation testing as a means of predicting survival or making treatment recommendations.

Target population

Adult patients (age ≥ 18 years) who have suspected WHO grade II diffuse glioma.

Question

Does the addition of intraoperative optical histologic methods provide accuracy beyond the use of conventional histologic methods in diagnosis and management?

Recommendation

There is insufficient evidence at this time to suggest that intraoperative optical histologic methods offer increased diagnostic accuracy when compared to conventional techniques.